AbbVie (NYSE:ABBV) Releases FY 2025 Earnings Guidance

AbbVie (NYSE:ABBV - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 11.670-11.870 for the period. The company issued revenue guidance of -. AbbVie also updated its Q2 2025 guidance to 2.840-2.880 EPS.

Analysts Set New Price Targets

ABBV has been the topic of several research analyst reports. Bank of America lifted their price objective on shares of AbbVie to $204.00 and gave the stock a "hold" rating in a research report on Monday, June 9th. Wall Street Zen cut shares of AbbVie from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Erste Group Bank upgraded shares of AbbVie to a "strong-buy" rating in a report on Monday, March 17th. Citigroup boosted their price target on shares of AbbVie to $205.00 and gave the company a "hold" rating in a report on Wednesday, June 11th. Finally, Cantor Fitzgerald assumed coverage on shares of AbbVie in a report on Tuesday, April 22nd. They set an "overweight" rating and a $210.00 price target on the stock. Eight research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, AbbVie currently has a consensus rating of "Moderate Buy" and an average price target of $211.29.

AbbVie Stock Performance

Shares of ABBV traded down $1.84 during trading hours on Monday, reaching $187.44. 10,162,022 shares of the company traded hands, compared to its average volume of 6,269,187. The stock has a market cap of $331.09 billion, a P/E ratio of 79.76, a price-to-earnings-growth ratio of 1.26 and a beta of 0.48. The stock's fifty day moving average is $187.37 and its 200 day moving average is $188.68. AbbVie has a 1-year low of $163.81 and a 1-year high of $218.66. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.40 by $0.06. The firm had revenue of $13.34 billion during the quarter, compared to analyst estimates of $12.91 billion. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The company's quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.31 earnings per share. Equities research analysts anticipate that AbbVie will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 annualized dividend and a yield of 3.50%. AbbVie's dividend payout ratio is 279.15%.

Institutional Trading of AbbVie

An institutional investor recently raised its position in AbbVie stock. Brighton Jones LLC raised its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 17.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,912 shares of the company's stock after acquiring an additional 3,401 shares during the quarter. Brighton Jones LLC's holdings in AbbVie were worth $4,072,000 as of its most recent SEC filing. Institutional investors own 70.23% of the company's stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.